Measles virus (MV) infections have been almost eradicated in some industrialized nations. However, MV continues to cause severe disease and mortality in the world and is responsible for clusters of exogenous-borne disease in essentially disease-free countries. Because of the ebb and flow of immunization campaigns, especially in the poverty-stricken and war-torn Third World, and the ominous potential for severe disease and mortality, it is vital that research for discovery of therapeutic countermeasures should continue. To that end, a number of compounds have been evaluated for efficacy in vitro and in animal models, and several therapeutic modalities have been tested in the clinic. The only current therapies used in the clinic include ribavirin administered orally or intravenously, alone or in combination with immune serum globulin; these therapies have demonstrated variable efficacy. Therefore, drug discovery efforts have been launched to supplement the existing treatments for MV infections. Antisense molecules, adenosine and guanosine nucleosides, including ring-expanded 'fat' nucleoside analogues, brassinosteroids, coumarins, peptide inhibitors, modulators of cholesterol synthesis and a variety of natural products have been screened for efficacy and toxicity both in vitro and in animals. However, none of these agents has gone into human clinical trials and most will not merit further development due to toxicity concerns and/or low potency. Thus, further research is needed to develop more potent and less toxic drugs that could be used for treating MV infections to supplement the existing MV vaccine campaigns.
Measles virus (MV) is a human pathogen that is a member of the Paramyxoviridae, which also includes other human pathogens such as respiratory syncytial virus (RSV), mumps, rubella, parainfluenza viruses 1-4 and the recently characterized human metapneumovirus (Griffin, 2003) .
Throughout history, MV has been notorious for causing severe mortality in susceptible or naive populations. In recent years, it is estimated that 30-40 million MV infections occur worldwide annually, leading to 1-2 million deaths per year , making it one of the 10 leading causes of death worldwide . For this reason, it is alarming whenever immunization levels drop in any country; a phenomenon that could lead to a cohort of individuals never exposed, but very susceptible, to MV infection. These lapses in MV immunization are happening despite massive immunization campaigns and the potential that MV could be eradicated, as was smallpox, through such intervention (Hinman, 2000) . Some of the vaccine coverage problem may be attributed to unfounded concerns over the safety of the measles, mumps and rubella (MMR) vaccine. As a result, there has been a decreased immunization coverage in areas such as the UK (Soldatou & Davies, 2003) and, more ominously, an increase in the number of susceptible individuals in areas once thought to be free of endemic cases (Carlowe, 2003) . In the US, the virus is also no longer considered endemic (Rota et al., 2002) ; nevertheless, re-introduction of the virus can still cause repeated, limited outbreaks (Gay, 2000) . In addition, it is thought that MV immunity from the vaccines wanes (Clements & Cutts, 1995) ; this could result in outbreaks in the elderly or cancer patients and in the healthcare workers who attend them (Steingart et al., 1999; Seo et al., 2002) .
Of additional concern is that MV demonstrates genotypic variability as do other RNA viruses , and it appears that disparate genotypes can cocirculate in a given geographical area at one time (Katayama et al., 1995; Jin et al., 1998 , Santibanez, et al., 2002 . Vaccine failures, which have occurred from time to time, may have been caused by such variants (Katayama et al., Introduction ©2004 International Medical Press 0956-3202/02/$17.00 1995) as evidenced by the fact in one study a number of individuals had low neutralizing antibody titres to several prevalent strains of MV including the Moraten vaccine strain ( Jin et al., 1998) .
Although MV is highly contagious and notorious for causing severe acute, sometimes lethal, infections it can also cause chronic diseases. The severity of acute disease appears to be largely mediated by the host immune response or lack thereof (Griffin, 2003) . Normally, the acute response leads to viral clearance and long-term immunity. However, the infection can lead to a fulminant pneumonitis and subsequent death, often in individuals who are immunocompromised (Griffin, 2003) . Treatment reagents for such infections are limited to ribavirin and/or immune serum globulin and have been variably successful in limiting severe morbidity and mortality (Stogner et al., 1993; Carmena et al., 1996) .
In contrast, persistent, chronic infections seem to be limited to the central nervous system in the form of subacute sclerosing pan encephalitis (SSPE) or measles inclusion body encephalitis (MIBE) (Carter & ter Meulen, 1983; Schneider-Schaulies et al., 2003) , which seem to be untreatable with current therapeutics to which wild-type MV is susceptible.
In recent years, attempts have been made to establish causality between MV infections, especially those attributable to vaccine usage, and persistent diseases such as autism (Singh et al. 2003; Kawashima, et al., 2000) , Crohn's disease (Kawashima, et al., 2000; Lavy et al., 2001) and multiple sclerosis (Cosby et al., 1989; Zorzon et al., 2003) . However, the linkages to MV as a causal agent of these diseases are tenuous, supported only by case study risk assessments or not supported at all by current epidemiological data ( Jack, 2004; Zorzon et al., 2003; Jefferson et al., 2003) .
Potential targets
MV is a single-strand RNA-containing virus that replicates within the cytoplasm of infected cells. It contains a negative sense (-) RNA genome of 15894 nucleotides. The virion contains two surface glycoproteins, haemagglutinin (H) and fusion (F), which induce neutralizing antibody (Griffin, 2003) . The H protein mediates viral attachment to cells and is largely responsible for the induction of neutralizing antibody (Griffin, 2003) . Because the H protein interacts with CD46, the cellular receptor for MV attachment, it can trigger the downregulation of CD46 (Krantic et al., 1995) . The F and H proteins are expressed on infected cell surfaces, allowing the virus to be spread from cell to cell without being exposed to the external environment where it could be eliminated by the immune system or inactivated by antiviral chemotherapeutics. In addition, the virus codes for a number of non-structural proteins, includ-ing the L protein, a catalytic component of the viral polymerase, a nucleoprotein (N), a phosphoprotein (P) which complexes with the L protein, V and C proteins and a matrix protein (M) (Griffin, 2003) . Targets for therapeutic intervention might include attachment mediated by the CD46 ligand, the binding of MV nucleoprotein to a cellular NR receptor leading to immunosuppression (Laine et al., 2003) , fusion, maturation of the F protein mediated by subtilisin-like endoproteases such as furins (Bolt & Peterson, 1998) , the interferon inhibiting activities of the V and C proteins (Shaffer et al., 2003; Takeuchi et al., 2003) , and the viral RNA-dependent RNA polymerase. Inhibition of MV-induced apoptosis might also be an intervention strategy (Esolen et al., 1995) .
Current/potential therapies

Clinical studies
There are effective live attenuated vaccines available to prevent MV infections. However, as previously mentioned, a significant proportion of any given population may be unprotected by such vaccines. Consequently, there have been studies to determine the efficacy of certain therapeutic agents for treating MV infections. Thus, ribavirin, interferon alpha and immune serum globulin (ISG) have been used clinically for treating MV infections. Interferon-alpha was not clinically beneficial (Wyde, 1999) , although ribavirin (Stogner et al., 1993) and ISG (Carmena et al., 1996) were shown to effectively reduce MV-induced respiratory distress. Ribavirin, given alone and intravenously (iv) (Forni et al., 1994) or orally, beneficially ameliorated MV-induced disease (Gururangan et al., 1990) . These findings are in contrast to case reports that ribavirin, given iv or by small particle aerosolization, achieved no clinical benefit for the patients treated with these dosage regimens (reviewed by Wyde et al., 2002) . Ribavirin in combination with ISG, given intravenously, also efficaciously reduced disease due to MV infections (Stogner et al. 1993 ). However, for SSPE, a combination of intrathecal high-dose interferonalpha and intravenous ribavirin administered at an early stage of SSPE seems to be effective (Hoppen et al., 2003) .
There also have been a number of reports on using vitamin A supplementation therapy for treating MV infections (Barclay et al., 1987 , Coutsoudis et al., 1991 Hussey & Kline, 1993; D'Souza & D'Souza, 2002) . This was probably inspired by the finding that MV infections cause vitamin A deficiency (D' Souza & D'Souza, 2002) . In one report, it was used effectively to ameliorate MV infections in hospitalized South African paediatric patients. In this study, measles-related mortality was reduced and the treatment appeared to shorten the length of the hospitalization required by patients (Hussey & Kline, 1993) . In fact, the World Health Organization (WHO) recommends high-dose vitamin A supplementation for all children with measles in countries where the case fatality rate for MV infections exceeds 1% (D' Souza & D'Souza, 2002) Nonclinical studies-synthetic and natural product inhibitors
Synthetic inhibitors
Antisense molecules. Several reports have been published on antisense inhibitors targeting either the nucleoprotein (N) gene (Koschel et al., 1995) or the haemagglutinin (H) gene (Koschel et al., 1995; Bell et al., 1997) .
In one study, antisense mRNAs complementary to the MV nucleoprotein N, or haemagglutinin H genes, were placed into vectors and transfected into three different types of cells (Koschel et al., 1995) . In infected, transfected Vero cells, there was a 90-99% reduction in the yields of infectious virus. Plaque numbers and plaque size were also significantly reduced compared with untransfected Vero cells. The activity was virus-specific, since no effects were seen in transfected Vero cells infected with vesicular stomatitis virus. After transfection of C6 rat glioma cells, which are normally suitable for establishing persistently MVinfected lines or in persistently infected C6/SSPE cells, no evidence of viral replication was detected. In addition, single cell clones from the antisense-transfected C6/SSPE cells appeared to be completely free of virus when cocultivated with Vero cells.
In another study, a recombinant expression plasmid was designed to produce antisense oligonucleotides targeted to the 5′ end of the MV nucleocapsid protein mRNA in human cervical epithelial adenocarcinoma cells (HeLa) (Bell et al., 1997) . The transfected cell line and a control cell line expressing 'scrambled' RNA with the same nucleotides were both infected with MV. Both viral cytopathic effect and infectious virus were reduced by approximately 90% in the antisense-expressing cell line, compared to that detected in control cells or in transfectant cells expressing random RNA. The effect was MV-specific, since there was no inhibition of mumps virus in either transfected cell line.
Adenosine analogues. A number of adenosine analogues have been synthesized which have broad-spectrum inhibitory properties against RNA viruses, including neplanocins (De Clercq, 1985) and noraristeromycins (Patil et al., 1992) , with S-adenosylhomocysteine hydrolase the likely target (De Clercq & Cools, 1985) . Neplanocin A and a number of derivatives have been shown to inhibit MV as well as other RNA viruses (Shuto et al., 1992; Shigeta et al., 1992; Niizuma et al., 1997) . Several early reports also noted the inhibition of MV replication in vitro by 5′-noraristeromycin and some derivatives (Patil et al., 1992; Siddiqi et al., 1993; Seley, et al., 1997) . However, both (+/-)-5′-noraristeromycin (Patil et al., 1992) and 3-deaza-5′-noraristeromycin (Siddiqi et al., 1995) , two of the more active compounds, were also broad-spectrum virus inhibitors.
Based on the past studies of carbocyclic adenosine analogues previously mentioned, a number 5′-nor carbocyclic adenosine analogues were evaluated for selective inhibition of MV replication (Barnard et al., 1999) . Several compounds inhibited MV selectively and potently with EC 50 values of <400 ng/ml, including (
In combination with ribavirin, all three compounds demonstrated the additive inhibition of MV. The compounds were not very cytotoxic in actively growing or resting cells. The mechanism of inhibition remains unknown, although the specificity of the MV inhibition suggests that the compounds are not Sadenosyl homocysteine hydrolase inhibitors, which often show a broad spectrum of viral inhibition (De Clercq et al., 1989; Robins et al., 1992) .
Guanosine analogues. As previously mentioned, ribavirin has been shown in clinical studies to ameliorate MVassociated disease. However, viramidine, the 3-carboxamide analogue of ribavirin, was not inhibitory to MV replication in vitro (Barnard, 2002) . Other analogues of guanine have also been studied, including 5-ethynyl-1-(3-δ-ribofuranosylimidazole-4-carboximide (EICAR). In vitro, EICAR had EC 50 values similar or better than those values for ribavirin (De Clercq et al., 1991; Shigeta, et al., 1992) . In a cotton rat model for MV infection, EICAR (total dose=120 mg/kg) reduced viral lung titres to levels threefold lower than ribavirin (total dose=360 mg/kg) when administered parenterally twice daily (Wade et al., 2000) .
Ring-expanded 'fat' nucleoside analogues. These compounds are a novel set of purine analogues with an expanded ring structure designated as a 5:7-fused imidazo[4,5-e][1,3] diazepine ring (Chen & Hosmane, 2001) . Two compounds in this series modestly inhibited virus replication in vitro, 6-amino-4,5-dihydro-8H-2-phenyl-1-(β-D-ribofuranosyl)imidazo[4,5-e][1,3] diazepine-4,8dione and 4,5-dihydro-8H-2-(N-ethyl)amino-1-(β-Dribofuranosyl)imidazo[4,5-e][1,3] diazepine-4,8-dione (Zhang et al., 2002) . Both of these compounds had hydrophobic substitutions at the two and six positions, respectively relative to the inactive parent compound. Both compounds had EC 50 values below 10 µM by CPE reduc-tion assay and neutral red uptake assay and were not toxic in resting CV-1 cells. The antiviral activity was independent of any virucidal activity. However, the mode of inhibiting MV replication remains unknown.
Mycophenolic acid (MPA) and mycophenolate mofetil (MMF) . Early studies suggested that MPA was a good inhibitor of MV replication in vitro (Cline et al., 1969) . Later MMF, an analogue of MPA, was shown to be more efficacious in vitro than ribavirin (Kosugi et al., 1994) .
Brassinosteroids. Brassinosteroids are a novel group of plant steroids essential for normal growth and development (Wachsman et al., 2002) . Natural brassinosteroids studied to date all contain a 5-α-cholestan skeleton. Structural variation occurs because of the type and position of functional groups on the cholestan nucleus and/or the stereochemistry of the A and B rings and the side chain (Wachsman et al., 2002) . In a study evaluating 27 brassinosteroid derivatives (natural and synthetic), five were found to selectively inhibit MV infection in vitro, [(22S,23S)-3β-Bromo-5α,22,23-trihydroxystigmastan-6one], [(22R,23R)-2α,3α,22,23-tetrahydroxy-β-homo-7oxastigmastan-6-one], [(22R,23R)-3β-fluoro-22,23-dihydroxystigmastan-6-one], [(22S,23S)-3β-fluoro-5α,22,23trihydroxystigmastan-6-one] and [(22S,23S)-5α-fluoro-3β-,22,23-trihydroxystigmastan-6-one]. The first compound was also found to inhibit Junin virus. The EC 50 values for the five active compounds, as determined by virus yield reduction assay, ranged from 1-8 mM. Cytotoxicity of the compounds was measured in stationary cells and ranged from 43 mM to 427 mM. Given that the compounds were only effective at millimolar concentrations, they will not be clinically useful because of the high doses that may be required to achieve an antiviral effect. The mechanism of inhibition of MV replication is unknown for these compounds, although they probably did not inhibit attachment nor did they likely physically disrupt the virion, since they only inhibited virus replication after virus adsorption.
Cholesterol synthesis inhibitors
Two inhibitors of cholesterol synthesis, W-7 and cerulenin, delayed syncytia formation in Vero cells infected with MV (Malvoisin & Wild, 1990) . At non-toxic doses, W-7 also inhibited the synthesis of infectious virus. Syncytia formation and changes in membrane cholesterol induced by these drugs were evaluated by labelling cell lipids with [ 14 C]acetate in the presence and absence of both drugs in infected and uninfected cells. The inhibition of syncytia by W-7 and cerulenin seemed to be associated with their capacity to alter the cholesterol metabolism. Thus, as might well be predicted, the well-characterized inhibitors of cholesterol synthesis, mevinolin, ketoconazole and miconazole were also shown to inhibit the syncytia formation. However, in antiviral assay, W-7 but not cerulenin inhibited virus replication. The antiviral effect of W-7 appeared not to be related to the capacity to prevent syncytium formation.
Coumarins.
A series of coumarin and pyranocoumarin analogues were evaluated in vitro for antiviral efficacy against MV replication in African green monkey kidney cells (CV-1) . Of the 22 compounds tested for inhibition, six were found to selectively inhibit MV. The active compounds included 5-hydroxy-7-propionyloxy-4-propionylcoumarin; 5,7-bis(tosyloxy)-4-propylcoumarin; 5-hydroxy-4-propyl-7-tosyloxy-coumarin; 6,6dimethyl-9-pivaloyloxy-4-propyl-2H,6H-benzo[1,2-b:3,4-b′]dipyran-2-one; 6,6-dimethyl-9-propionyloxy-4-propyl-2H,6H-benzo[1,2-b:3,4-b′]dipyran-2-one and 7,8-cis-10,11,12-trans-4-propyl-6,6,10,11-tetramethyl-7,8,9,-trihydroxy-2H,6H,12H-benzo[1,2-b:3,4-b′:5,6-b′′]tripyran-2-one. The first three drugs are propyl coumarin analogues, the fourth and fifth are dipyrano coumarins and the last compound is a benzotripyranone with a coumarin nucleus.
The EC 50 values for these six compounds ranged from 300 ng/ml to 5000 ng/ml as assessed by neutral red uptake assay. By virus yield reduction assay, the EC 90 values were 300 to 3000 ng/ml, with the first compound mentioned having an EC 90 of 40000 ng/ml. Most of the six compounds inhibited all ten MV strains evaluated. The antiviral activity was independent of any virucidal activity. One compound tested in combination with ribavirin did not significantly interact with ribavirin. The compounds exhibited variable cytotoxicity in cell culture with IC 50 values ranging from 1000 to 100000 ng/ml in both resting and actively growing cells. The analogues appeared to inhibit virus replication at all times of addition, although a low MOI was used in the timing assays; this means that the data could be interpreted as indicating that the spread of virus was merely inhibited. The mode of inhibiting MV replication remains undetermined, although other coumarin-like compounds have been shown to inhibit HIV reverse transcriptase (Bourinbaiar et al., 1993) , HIV-1 integrase (Zhao et al., 1997) , HIV-1 protease (Skulnick et al., 1999) , vaccinia DNA topoisomerase (Sekiguchi, 1996) and protein kinase C (Yang et al., 1999) .
N-(phosphonoacetyl)-L-aspartate (PALA). PALA is a potent inhibitor of L-aspartic acid transcarbamylase. In vitro, it inhibited MV replication in African green monkey kidney cells (Vero) in virus cytopathic effect reduction assay with an EC 50 =8 µg/ml (Wyde et al., 1995) . Although not evaluated in vivo for inhibition of MV, in cotton rats the compound was not toxic even at 100 mg/kg/day for 7 days. However, in vitro, the compound was cytotoxic in actively growing cell cultures, which does not bode well for further development because of the potential for toxicity in children and fetuses (such as with ribavirin).
Polyaminopropane sulphate (PAMPS) . PAMPS was reportedly a strong selective inhibitor of MV infection in vitro (Wyde et al., 2000) with a selective index of >200 in a marmoset lymphocyte cell culture (B95-8 cells) assay. In the cotton rat model for MV infection, PAMPS, administered intranasally (in), was very inhibitory to virus titres in the lung, although the inhibition was highly dependent on the time of addition of the drug relative to virus exposure in the animal. The compound was most effective in reducing virus titres when administered within 5 min after virus exposure. Loss of efficacy was seen even when the interval between virus exposure and drug administration was only 15 min. Thus, PAMPS was only effective in preventing the establishment of virus infection; it was not therapeutically efficacious. The reason for this may be due to its putative mode of inhibition, which is postulated to be inhibition of viral attachment. If the virus is allowed to establish an infection, then PAMPS would not inhibit its further spread because of the predilection of MV to spread from cell to cell via fusion (Griffin, 2003) . In addition, it could be that the drug might not have achieved adequate dispersal concentrations within the lung to effectively inhibit the attachment of all infectious virions (Wyde et al., 2000) .
Synthetic peptides
Several studies have evaluated the effects of carbobenzoxy peptides and other peptides on MV replication and the fusogenic capabilities of MV (Miller et al., 1968; Nicolaides et al., 1968; Lobl et al., 1988; Lambert et al., 1996) . In addition, a cowpea virus was constructed to express an inhibitory peptide that was designed to prevent attachment of MV to the CD46 receptor (Khor et al., 2002) .
Five carbobenzoxylated and D-amino acid containingpeptide analogues of the RSV F1 glycoprotein amino terminus were chemically synthesized by solution and FMOC-solid phase peptide synthesis methods (Lobl et al., 1988) . Two of these compounds, CBZ-D-Phe-L-Leu-Gly-D-Phe-D-Leu-D-Leu and CBZ-D-Phe-L-Leu-Gly-D-Phe-D-Leu-D-Leu-Gly, inhibited MV replication by CPE reduction assay at 62 µg/ml. These peptide analogues of RSV F1 glycoprotein had non-specific effects on membranes because of their membrane-stabilizing capabilities, which may have resulted in the anti-MV activity.
Substance P, a neuropeptide of the tachykinin group, inhibited MV replication in cell culture and partially blocked viral fusion activity assayed in a haemolysis assay (Schroeder, 1986) . The IC 50 was 0.6 µM, although the effect was completely reversible. This tachykinin shared short homology with the N-terminus of paramyxovirus fusion proteins and presumably acted as competitive fusion inhibitor.
In another approach, conserved heptad repeat domains analogous to the DP-107 and DP-178 regions of HIV-1 gp41 were identified within the glycoproteins from other fusogenic viruses, including MV (Lambert et al., 1996) . Various peptide preparations with antiviral activity were purified and tested for their ability to block syncytium formation. The MV-specific peptide blocked MV-mediated syncytium formation with EC 50 values ranging from 0.015-0.250 µM.
In another study, the plant virus cowpea mosaic virus (CPMV) was used as a biomolecular platform to display a peptide known to inhibit MV attachment in vitro (Khor et al., 2002) . This peptide sequence corresponded to a portion of the MV binding site on the human MV receptor CD46. The CPMV-CD46 chimera inhibited MV infection of HeLa cells and protected mice from mortality induced by an intracranial challenge with MV. The chimera was also up to 100-fold more effective than the soluble CD46 peptide at inhibiting MV infection in vitro.
Natural product inhibitors
Included in the list of natural products evaluated for inhibition of MV are compounds such as spicebrush, a Cherokee folk remedy for certain infections including MV infections (McWhorter, 1996) , plant biflavonoids (Lin et al., 1999) , a Chinese herbal called Shengma-Gegen-Tang (Huang et al., 1997) , Japanese, Indonesion and Chinese traditional medicines (Kurokawa et al., 1993) , calcium spirulan, a sulphated heteropolysaccharide from a blue-green alga (Hayashi et al., 1996) , plant leaf extracts from Macaranga kilimandscharica (Cos et al., 2002) , SP-303 (Provir), a proanthocyanidin oligomer (Wyde et al., 1993) and Crotolus durissus venom (Petricevich & Mendonca, 2003) .
Several varieties of natural products have been evaluated for inhibition of MV replication in cell culture. In one study, five groups of plant biflavonoids were isolated from the medicinal plants, Rhus succedanea and Garcinia multiflora. The various classes of extracted compounds inhibited a number of viruses including respiratory viruses (influenza A, influenza B, parainfluenza type 3, RSV, adenovirus type 5 and measles) and herpes viruses [HSV-1, HSV-2, HCMV and varicella zoster virus (VZV)] (Lin et al. 1999) . The biflavonoid, succedaneflavanone, was the only compound to selectively inhibit MV, although the compound was cytotoxic as well.
Another compound, Shengma-Gegen-Tang, was evaluated against MV in human peripheral blood mononuclear cells (PBMC) as well as in Vero cells (Huang et al., 1997) . One hundred µg/ml Shengma-Gegen-Tang suppressed release of MV from PMBC after 8 days of infection, but this suppression was not detected in Vero cells. In addition, Shengma-Gegen-Tang selectively stimulated the secretion of TNF-alpha in PBMC. Time kinetic analysis indicated that the stimulation was rapid and could be detected only 2 h following the treatment of the PBMC and was optimal from 8-12 h post compound exposure. It may well be that the antiviral efficacy of Shengma-Gegen-Tang was due, in part, to modulation by TNF-alpha.
Other traditional medicines from China, Indonesia and Japan were examined for the antiviral activity of their hot water extracts against herpes simplex virus type 1 (HSV-1), poliovirus type 1 and MV by plaque reduction assays (Kurokawa et al., 1993) . Thirty extracts inhibited MV plaque formation. Three extracts that inhibited HSV-1 replication also inhibited MV.
Calcium spirulan was effective in reducing plaques by 50% at 32 µg/ml when added 1 h after virus exposure and by 50% at 17 µg/ml when cells were pretreated with compound prior to virus exposure (Hayashi et al., 1996) . The compound was relatively nontoxic in actively growing cells. A mode of action study with HSV-1 determined that calcium spirulan inhibited virus penetration.
Leaf extracts from Macaranga kilimandscharica reduced MV titres by 1000 at the maximal non-toxic dose (1/20) (Cos et al., 2002) . The active component remains unidentified.
The antiviral activity of an aqueous extract of Podophyllum peltatum was fractionated by reversed-phase chromatography (Wyde et al., 1993) . Only a fraction identified as a podophyllotoxin inhibited the replication of MV, but also inhibited HSV-1 replication. The compound is virucidal, extremely toxic in cell culture, and probably inhibits viral attachment (author's unpublished data).
SP-303 (Provir TM ), from the latex of an Amazonian plant, Croton lechleri, is a complex proanthocyanidin oligomer (Ubillas et al., 1994) . It was found to have broad-spectrum activity against both DNA viruses (Barnard et al., 1993a) and RNA viruses, especially paramyxoviruses such as RSV (Barnard et al., 1993b) and MV (Wyde et al., 1993) . It appeared to be an attachment/penetration inhibitor (Barnard et al., 1993b) . However, it was very cytotoxic in actively growing cells, as measured by the lack of uptake of radiolabelled macromolecule precursors (Barnard et al., 1993b) .
The Crotolus venom component was not toxic in Vero cells at concentrations below 100 mg/ml and was inhibitory to MV replication with an EC 50 =0.1 µg/ml when added before virus exposure and inactive when added after virus exposure, suggesting that compound inhibited virus attachment or was virucidal (Petricevich & Mendonca, 2003) .
Conclusions
Measles virus is an immunosuppressive virus that can cause very severe or life-threatening disease (Griffin, 2003) . However, a highly effective vaccine is available and its prudent use could result in the eradication of MV infections whenever appropriate immunization strategies are used, such as with endogenous infections in the US. Nevertheless, the virus still causes enough infections throughout the world to be one of the leading causes of death in the world due to infectious disease . This necessitates, even in areas where MV is no longer endemic, massive, prolonged and stringent immunization campaigns to prevent the establishment of endogenous infections where MV has been eliminated (as happened in the UK) and to facilitate eradication of the virus in areas where infection is still endemic.
With some evidence that immunity from the vaccine is not lifelong (Clements & Cutts, 1995) , it behoves the public health systems of nations to continue stressing immunization, especially to protect healthcare workers with waning immunity, the elderly and the immunocompromised. Any generational lapse in protection from immunization could result in the establishment of a cohort of individuals who would be susceptible to morbidity and mortality due to MV, which could be of historical proportions. At the very least, such gaps in vaccine coverage will allow the reestablishment of endogenous infections in areas now free of disease. This suggests that there is also a need to have effective therapies for individuals not protected by the vaccines for any reason, such as the lack of neutralizing antibody in response to the vaccine used (Katayama et al., 1997) . Thus, there should probably be at least two therapeutic countermeasures in place with different mechanisms of action, as has been recommended for smallpox (LeDuc et al., 2002) .
The current therapies used in the clinic consisting of ribavirin administered orally or iv, alone or in combination, with ISG are variably effective (reviewed by Wyde et al., 2002) . Because of the teratogenicity and anaemia associated with ribavirin therapy, it would be desirable to have a compound with less potential toxicity and that was easier to deliver (Lin et al., 2004) .
As indicated previously, the greatest impact of MV disease is outside the US, where it is one of the top infectious diseases causing mortality. Disease resulting from this virus has been deemed significant enough to warrant the inclusion of MV on the list of respiratory viruses that the United States National Institutes of Health has evaluated in their antiviral research programme for the past 15 years. Unfortunately, MV disease is not serious in the US and thus US pharmaceutical companies are less likely to develop MV inhibitors, unless they happen to also be broad-spectrum paramyxovirus inhibitors.
None of the compounds discussed in this review have gone into human clinical trials, and many probably do not merit further development due to toxicity concerns and/or low potency. Thus, further research is required to develop the necessary countermeasures to supplement the vaccinebased eradication of MV disease, to potentially treat the immunocompromised and elderly and those with waning immunity, and to have effective therapeutic agents available when natural antigenic shifts occur that could render the current vaccines less efficacious or perhaps impotent.
